Please scroll down to view our articles and photos. Thank you for your visit.

banner of sunburstglobalhealthnews.com
 
Home Sunburst Store More Health News/Reports About Us
 






JoAnne Green, Founder/Editor,/Publisher
JoAnne Green














Northwestern Study Tests Drug Against Parkinson's Disease

Tanya Simuni, M.D., medical director of Northwestern University's Parkinson's Disease and Movement Disorders Center, was awarded a grant from the National Institutes of Health (NIH) to conduct a $16 million phase III study of the safety and efficacy of the drug isradipine as a potential neuroprotective agent in Parkinson's disease.

This is the only phase III Parkinson's neuroprotective study currently funded by the National Institute of Neurological Disorders and Stroke at NIH. The research is being conducted by Northwestern University Feinberg School of Medicine in partnership with the University of Rochester Medical Center. The study will be carried out at 56 Parkinson Study Group centers in North America over five years.

"If this drug proves to be safe and effective, it will change the way we treat Parkinson's disease," said Simuni, the principal investigator of the study. "The major advantage is isradipine is already widely available and inexpensive and will allow for rapid translation of our research into clinical practice. Although we now have very effective symptomatic treatments to manage Parkinson's, the development of a disease-modifying intervention remains the Holy Grail."

Simuni is the Arthur C. Nielsen, Jr. Research Professor in Parkinson's Disease and Movement Disorders at Feinberg and a neurologist at Northwestern Memorial Hospital.

Parkinson's is the second most common neurodegenerative disease. Prominent traits include tremor, stiffness of the limbs and trunk, slowness of movement and impaired balance and coordination. While there are pharmaceutical and alternative therapies available to manage the disease, there are currently no cures or treatments that definitively slow its progression. Researchers are looking for treatments to delay disease progression. If isradipine proves effective, the drug could revolutionize the treatment of Parkinson's.

Isradipine has been approved by the Food and Drug Administration as a calcium-channel blocker to treat hypertension (high blood pressure). By inhibiting the excessive flow of calcium, it may also stunt certain adverse cellular functions.

Researchers have speculated that imbalances in calcium may contribute to cellular toxicity and the death of dopamine-producing neurons in the brain that lead to Parkinson's. Dopamine is a critical chemical messenger in the brain that directs a person's ability to move. It is hypothesized that isradipine will slow the progression of the disease by protecting dopamine-producing neurons from toxicity over an extended period of time.

Academic colleagues at Feinberg will collaborate with Simuni on this study, including D. James Surmeier, the Nathan Smith Davis Professor of Physiology and director of the Udall Center of Excellence for Parkinson's Disease Research. Surmeier, the chair of physiology, and his team of researchers discovered the possible relationship between isradipine and Parkinson's disease. The physiology department Surmeier heads is one of the nation's premier groups studying the physiology of movement disorders.


Save up to 75% on Vitamins, Herbs and Supplements


Click here to connect with us on Facebook.

Click here to like us on Facebook.




Click here to like us on Facebook.




Most Viewed Articles

Walking May Help Protect Kidney Patients Against Heart Disease and Infections

Food Helps Older Generation Age Successfully

Cosmetic Treatment Can Open the Door to Bacteria

Food Allergy Nearly Doubles Among Black Children
 
How bacteria communicate with us to build a special relationship

Vegetables Can Make You Look Like a Hero, and a Better Cook

Promising Cervical Cancer Study

Better Broccoli, Enhanced Anti-Cancer Benefits with Longer Shelf Life




 



 
Home  Sunburst Store More News/Reports About Us Privacy Pledge Terms of Use Site Map

Copyright © 2017 Sunburst Worldwide Enterprises. All rights reserved.
Warning: All of the pages on this site are protected under U.S. and International Copyright laws.
Reproduction by any means or for any purpose, except as specified on certain pages, is not allowed
 without the express written permission of the copyright owner.
SunburstGlobalHealthNews.com is an online publication of Sunburst Worldwide Enterprises.
By using this website, you agree to our Terms of Use.